Upstream therapy of atrial fibrillation

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 7, 2009, Pages 763-778

  Smit, Marcelle D ^a   Van Gelder, Isabelle C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atrial fibrillation; Atrial remodeling; Rhythm control

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; AMLODIPINE; ATENOLOL; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; ESTROGEN; FISH OIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; PRAVASTATIN; PREDNISONE; PROPAFENONE; RAMIPRIL; SOTALOL; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; CARDIOVERSION; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; GENETIC HETEROGENEITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE MODIFICATION; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRIMARY PREVENTION; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; SINUS RHYTHM; TREATMENT RESPONSE; ANIMAL; EXERCISE; METHODOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE;

ANIMALS; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; EXERCISE; HUMANS; PRIMARY PREVENTION; RECURRENCE; SECONDARY PREVENTION;

EID: 70349335388     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.59     Document Type: Review

References (97)

1. Van Gelder IC, Crijns HJ, Tieleman RG et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch. Intern. Med. 156, 2585-2592 (1996).
2. Ahmed S, Rienstra M, Crijns HJ et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 300, 1784-1792 (2008).
3. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
4. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
5. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358, 2667-2677 (2008).
6. Rienstra M, Van Gelder IC, Hagens VE et al. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study. Eur. Heart J. 27, 357-364 (2006). •In this subanalysis of the Rate Control versus Electrical Cardioversion of Persistent Atrial Fibrillation (RACE) study, effective rhythm control, that is, actual maintenance of sinus rhythm, was not associated with a superior prognosis compared with a rate-control strategy among patients who remained on warfarin throughout the study.
7. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur. Heart J. 27, 136-149 (2006).
8. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J. Am. Coll. Cardiol. 50, 2021-2028 (2007). (Pubitemid 350087568)
9. Smit MD, Van Gelder IC. Is inflammation a risk factor for recurrent atrial fibrillation? Europace 11, 138-139 (2009).
10. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 51, 802-809 (2008). •Thoroughly reviews the current literature on the role of atrial fibrosis as a substrate for atrial fibrillation (AF) with regard to underlying mechanisms and possible therapeutic approaches.
11. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968 (1995).
12. Nattel S, Shiroshita-Takeshita A, Cardin S, Pelletier P. Mechanisms of atrial remodeling and clinical relevance. Curr. Opin. Cardiol. 20, 21-25 (2005). (Pubitemid 40030306)
13. Cosio FG, Aliot E, Botto GL et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 10, 21-27 (2008). •Well-written paper discussing that treatment of AF should commence at the first-detected episode and that it should be based on a double strategy of restoration of sinus rhythm and treatment of conditions that promote atrial remodeling.
14. Van Gelder IC. Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue. Cardiovasc. Res. 74, 8-10 (2007).
15. Patlolla V, Alsheikh-Ali AA, Al Ahmad AM. The renin-angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin. Electrophysiol. 29, 1006-1012 (2006).
16. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am. J. Physiol Heart Circ. Physiol 284, H176-H184 (2003).
17. Tsai CT, Lai LP, Kuo KT et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 117, 344-355 (2008). •Well-conducted experimental study demonstrating the fibrotic effects of angiotensin II, which are attenuated by concomitant administration of losartan or simvastatin.
18. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace 10, 238-241 (2008). •Good overview of electrophysiological effects of angiotensin II.
19. Li D, Shinagawa K, Pang L et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104, 2608-2614 (2001). (Pubitemid 33104801)
20. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc. Res. 54, 456-461 (2002). (Pubitemid 34327924)
21. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45, 1832-1839 (2005).
22. L'Allier PL, Ducharme A, Keller PF et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J. Am. Coll. Cardiol. 44, 159-164 (2004). (Pubitemid 38976480)
23. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 45, 712-719 (2005).
24. Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J. Hypertens. 26, 403-411 (2008). (Pubitemid 351317247)
25. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107, 2926-2931 (2003).
26. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am. Heart J. 152, 86-92 (2006).
27. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 149, 548-557 (2005). (Pubitemid 40585420)
28. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100, 376-380 (1999). (Pubitemid 29362407)
29. Salehian O, Healey J, Stambler B et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am. Heart J. 154, 448-453 (2007). (Pubitemid 47271928)
30. Yin Y, Dalal D, Liu Z et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur. Heart J. 27, 1841-1846 (2006).
31. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106, 331-336 (2002).
32. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur. Heart J. 24, 2090-2098 (2003).
33. Palardy M, Ducharme A, Nattel S et al. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). Can. J. Cardiol. 24, 709-713 (2008).
34. Van Noord T, Crijns HJ, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc. Disord. 5, 3 (2005). (Pubitemid 40180359)
35. Tveit A, Grundvold I, Olufsen M et al. Candesartan in the prevention of relapsing atrial fibrillation. Int. J. Cardiol. 120, 85-91 (2007). (Pubitemid 47008995)
36. Van den Berg MP, Crijns HJ, Van Veldhuisen DJ et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J. Card Fail. 1, 355-363 (1995).
37. Belluzzi F, Sernesi L, Preti P et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J. Am. Coll. Cardiol. 53, 24-29 (2009).
38. Disertori M, Latini R, Barlera S et al. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606-1617 (2009).
39. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9, 1006-1023 (2007).
40. De Mello WC. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J. Renin. Angiotensin. Aldosterone. Syst. 7, 40-46 (2006).
41. Milliez P, Deangelis N, Rucker-Martin C et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur. Heart J. 26, 2193-2199 (2005).
42. Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 17, 534-541 (2006).
43. Gao X, Peng L, Adhikari CM, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J. Card Fail. 13, 170-177 (2007).
44. Mottram PM, Haluska B, Leano R et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110, 558-565 (2004).
45. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc. Res. 75, 10-20 (2007).
46. Adam O, Neuberger HR, Bohm M, Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 118, 1285-1293 (2008).
47. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110, 2313-2319 (2004).
48. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc. Res. 62, 105-111 (2004).
49. Fauchier L, Pierre B, de LA et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized, controlled trials. J. Am. Coll. Cardiol. 51, 828-835 (2008). •Meta-analysis of effects of statins on AF in controlled trials, demonstrating that statin use is significantly associated with a decreased risk of incidence or recurrence of AF.
50. Amar D, Zhang H, Heerdt PM et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128, 3421-3427 (2005).
51. Marin F, Pascual DA, Roldan V et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am. J. Cardiol. 97, 55-60 (2006). (Pubitemid 41828123)
52. Ozaydin M, Dogan A, Varol E et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 107, 117-121 (2007). (Pubitemid 46272262)
53. Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study. Circulation 114, 1455-1461 (2006).
54. Song YB, On YK, Kim JH et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am. Heart J. 156, 373-416 (2008).
55. Liakopoulos OJ, Choi YH, Haldenwang PL et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur. Heart J. 29, 1548-1559 (2008).
56. Virani SS, Nambi V, Razavi M et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am. Heart J. 155, 541-546 (2008).
57. Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol. 92, 1379-1383 (2003). (Pubitemid 37532555)
58. Pellegrini C, Vittinghoff E, Lin F, Hulley S, Marcus G. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: The HERS Trial. Heart 95, 704-708 (2009).
59. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am. Heart J. 154, 1140-1145 (2007).
60. Hanna IR, Heeke B, Bush H et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3, 881-886 (2006). (Pubitemid 44103516)
61. McLean DS, Ravid S, Blazing M et al. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am. Heart J. 155, 298-302 (2008).
62. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol. 92, 1343-1345 (2003).
63. Ozaydin M, Varol E, Aslan SM et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. 97, 1490-1493 (2006).
64. Humphries KH, Lee M, Sheldon R et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am. Heart J. 154, 908-913 (2007). (Pubitemid 350010927)
65. Tveit A, Grundtvig M, Gundersen T et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. 93, 780-782 (2004). (Pubitemid 38338579)
66. Almroth H, Hoglund N, Boman K et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur. Heart J. 30, 827-833 (2009).
67. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am. Heart J. 150, 1064.E7-1064.E12 (2005).
68. Gillis AM, Morck M, Exner DV et al. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation. Eur. Heart J. 29, 1873-1880 (2008).
69. Tsai CT, Lai LP, Hwang JJ et al. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial. Am. Heart J. 156, 65-70 (2008).
70. Glotzer TV, Hellkamp AS, Zimmerman J et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST). Circulation 107, 1614-1619 (2003).
71. Capucci A, Santini M, Padeletti L et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J. Am. Coll. Cardiol. 46, 1913-1920 (2005).
72. Bhavnani SP, Coleman CI, White CM et al. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace 10, 854-859 (2008).
73. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 296, 1885-1899 (2006).
74. London B, Albert C, Anderson ME et al. Ω-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Ω-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 116, e320-e335 (2007). (Pubitemid 47360222)
75. + current in human atrial myocytes. Cardiovasc. Res. 81, 286-293 (2009).
76. Sakabe M, Shiroshita-Takeshita A, Maguy A et al. Ω-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 116, 2101-2109 (2007). (Pubitemid 350060347)
77. Duda MK, O'Shea KM, Tintinu A et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc. Res. 81, 319-327 (2009).
78. Laurent G, Moe G, Hu X et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc. Res. 77, 89-97 (2008). (Pubitemid 351195152)
79. Sarrazin JF, Comeau G, Daleau P et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J. Am. Coll. Cardiol. 50, 1505-1512 (2007). (Pubitemid 47494587)
80. Calo L, Bianconi L, Colivicchi F et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Cardiol. 45, 1723-1728 (2005). (Pubitemid 40704512)
81. Mozaffarian D, Psaty BM, Rimm EB et al. Fish intake and risk of incident atrial fibrillation. Circulation 110, 368-373 (2004). (Pubitemid 38993844)
82. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am. Heart J. 151, 857-862 (2006).
83. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am. J. Clin. Nutr. 81, 50-54 (2005).
84. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc. Res. 69, 865-875 (2006). (Pubitemid 43227985)
85. Chaney MA, Nikolov MP, Blakeman B, Bakhos M, Slogoff S. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth. Analg. 87, 27-33 (1998). (Pubitemid 28311605)
86. Yared JP, Starr NJ, Torres FK et al. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann. Thorac. Surg. 69, 1420-1424 (2000).
87. Yared JP, Bakri MH, Erzurum SC et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J. Cardiothorac. Vasc. Anesth. 21, 68-75 (2007).
88. Halonen J, Halonen P, Jarvinen O et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized, controlled trial. JAMA 297, 1562-1567 (2007). (Pubitemid 46588369)
89. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. 25, 1100-1107 (2004). (Pubitemid 38842447)
90. Carnes CA, Chung MK, Nakayama T et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ. Res. 89, E32-E38 (2001).
91. Eslami M, Badkoubeh RS, Mousavi M et al. Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. Tex. Heart Inst. J. 34, 268-274 (2007). (Pubitemid 350057566)
92. Korantzopoulos P, Kolettis TM, Kountouris E et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int. J. Cardiol. 102, 321-326 (2005). (Pubitemid 40854050)
93. Lee KW, Everett TH, Rahmutula D et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114, 1703-1712 (2006). (Pubitemid 44607118)
94. Shimano M, Tsuji Y, Inden Y et al. Pioglitazone, a peroxisome proliferatoractivated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 5, 451-459 (2008).
95. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 118, 800-807 (2008). •Demonstrates that moderate exercise, not intensive exercise, is associated with a reduced incidence of AF.
96. Mont L, Tamborero D, Elosua R et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 10, 15-20 (2008). (Pubitemid 351767264)
97. Benjamin EJ, Chen PS, Bild DE et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 119, 606-618 (2009).